Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
about
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experienceTargeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinibBCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic LeukemiaAcalabrutinib (ACP-196): a selective second-generation BTK inhibitorPrevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapyThe potential of venetoclax (ABT-199) in chronic lymphocytic leukemiaSecond-generation inhibitors of Bruton tyrosine kinaseChallenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological MalignancyMature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications.Management of elderly and unfit patients with chronic lymphocytic leukemia.The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.Reappraising the timing of transplant for indolent non-Hodgkin lymphomas.Richter transformation of CLL.Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia.Personalized therapy tests for the monitoring of chronic lymphocytic leukemia development.A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.Disseminated Cryptococcosis With Brain Involvement in Patients With Chronic Lymphoid Malignancies on Ibrutinib.An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractorinessCirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison.Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with IbrutinibChronic lymphocytic leukemia therapy: new targeted therapies on the wayA Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic Leukemia.Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia.Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib.New Pharmacotherapies in Chronic Lymphocytic Leukemia.Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trialThe role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies.Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.Development of venetoclax for therapy of lymphoid malignancies.Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment.Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia.Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trialNew drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia.PHEDRA: using real-world data to analyze treatment patterns and ibrutinib effectiveness in hematological malignancies.
P2860
Q26738946-60833496-77D4-418B-9825-E0B9FCCC3501Q26744277-490E0FFB-DCCF-4554-948B-A6E349FADC88Q26765624-ECE6A11C-1A22-4581-9D5D-817F16750655Q28066316-FA969EAB-31A3-485C-8C2F-BE22F4485560Q28070090-CA1FAD96-4472-4526-BF2F-48B0B16D54C3Q28075504-B33911FA-C7C5-4B57-A0E9-93BBBA2CA02DQ28076118-96CA33C6-DD3F-4D5A-9054-D2CAF6E8C095Q28080304-03667204-7D6D-4325-B520-7C4EB10D988FQ30240133-2D01A260-F7B8-4DD5-8867-42B9F378EED8Q30243914-0CD09073-9F5E-4E6D-8423-C29AA08240F6Q30243968-D5D19489-100E-45C8-BBF0-478B13FFE8EEQ30248407-7C0CE25A-150D-4F6C-A7AE-D3A470E53F41Q30249283-9536B836-797E-4403-A982-925BCD8E2446Q30252869-41C6EED5-8E3F-48E1-ABD5-64F1C2BD15BCQ31097476-D4435E19-6440-4DBB-B351-F3C7378A1A31Q33438825-7352F156-8D8E-4EB7-958D-33F70944A428Q33439333-B61DB6D2-7066-42B3-91C7-7F139A36AD0EQ33598691-92AC18F0-C525-4E58-AAD2-30F49BCCCBEFQ33626106-2A287878-9E31-4D31-9719-887ADD8AD5FFQ33629021-97A01FF0-C83B-4E22-AEE9-A2AB74FB2A31Q33709543-0C64CF80-3FD5-4059-AC8E-A0B9126CB94BQ33774517-2482C0F1-D682-4DF7-BFE5-CEFA5F55DFB1Q33890828-35C382DB-F2E5-4EBA-8F0A-871614F02355Q36759082-6451BE9A-02F4-404E-B05A-7363BD7B6244Q37113544-227AFAC4-E025-411D-AC93-D0D6ABCC398CQ37321917-377B2709-4BBA-435D-A08F-F32D369662B3Q37429218-078A53A8-997E-457D-BFAC-7228C05D63EFQ37593573-38807087-9F0F-4EDB-962C-57A7F1E7E465Q37599562-B708C1AD-0A14-4BA3-A20B-F2C4DEE8E536Q37605306-07B88E62-72C7-413D-9EAD-2FBFF607F82FQ37633475-EB7EF124-47E0-409B-B5CF-193CEF9B86E7Q37638782-10153EC4-7702-4C49-B236-27DF705FDE56Q37688589-64083747-69D6-4C6D-AA52-39A14745004EQ37702281-EFE6BC79-0C08-4431-9053-ED7115AEBF58Q37706530-522D12EC-3C49-45D4-9CDC-8336B82A1C13Q37742056-4BD10B76-75FD-44E9-BCBE-94E244416947Q38612385-2F2DC6AA-AE5D-4F7F-8724-AB26025DF8C1Q38638639-FC3F1415-5D00-4CBD-9B93-0938529321F8Q38646974-82A042FD-108B-4691-AF45-66B9177CC617Q38647162-F3882404-C28E-47A7-B3AD-BB3D972EA406
P2860
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
@ast
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
@en
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
@en-gb
type
label
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
@ast
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
@en
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
@en-gb
prefLabel
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
@ast
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
@en
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
@en-gb
P2093
P2860
P50
P356
P1154
2-s2.0-84950133717
P1476
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
@en
P2093
Aaron Polliack
Alessandra Tedeschi
Andrzej Hellmann
Ann Janssens
Anna Schuh
Carolyn Owen
Danelle F James
David Simpson
Deepali Suri
Don A Stevens
P2860
P304
P356
10.1056/NEJMOA1509388
P407
P50
P5530
P577
2015-12-06T00:00:00Z
P6179
1011419396